Related to Biovail Acquires U.S. and Canadian Rights to Kyowa Hakko’s Parkinson Disease Drug Candidate

• Civitas Raises $20M for Parkinson Disease Program
  
• Merck Serono Partners with Domain to Develop mGluR4 PAM Candidates for PD
  
• Intranasal Delivery of MSCs Shown to Improve PD Symptoms in Rats
  
• GSK Nixes Neuroscience Collaboration with Targacept
  
• Study Finds PD Patients and Relatives Have Increased Risk of Melanoma and Prostate Cancer
  
• Death of Dopamine-Producing Cells in Parkinson Disease Linked with Mitochondrial Damage
  
• Envoy Awarded MJFF Grant to Develop Oral Drug for Parkinson Disease
  
• Studies Show SUMO Protects Alpha-Synuclein Against Fibril Formation and Neurotoxicity
  
• BioFocus Collaborates with Michael J. Fox Foundation on Parkinson Disease Diagnostic
  
• Impax and GSK Report Positive Data from Third Phase III Study with Parkinson Disease Drug
  
• Mutations in Stress Response Gene Identified in Parkinson Disease
  
• Investigators Get $8M to Set Up Parkinson’s Brain Bank
  
• MJFF Awards AFFiRiS $1.5M for Phase I Study with Peptide-Based Parkinson Disease Vaccine
  
• Merck Serono Hands Parkinson Disease Drug Safinamide Back to Newron
  
• Biotie Axes Agreement to Acquire Newron on Latter’s Loss of Partner for Parkinson Disease Drug
  
• Elan, Cambridge University Launch CNS Disease Drug Discovery Facility
  
• ProteoTech, GSK Come Together for Parkinson Drug R&D
  
• Oncodesign, Ipsen Seal Potentially $149M LRRK2 Inhibitor Parkinson Disease Deal
  
• Amarantus Pays Power3 $0.5M for Biomarker IP to Diagnose Parkinson Disease
  
• Santhera Regains Global Rights to Parkinson Disease Drug Fipamezole from Ipsen